BAM
MRNA icon

Bellevue Asset Management’s Moderna MRNA Stock Holding History

Bellevue Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$9K – 519
2022
Q1 		$9K Hold
50
– – 0.01% 316
2021
Q4 		$13K Hold
50
– – 0.01% 309
2021
Q3 		$19K Hold
50
– – 0.01% 289
2021
Q2 		$12K Hold
50
– – 0.01% 323
2021
Q1 		$7K Hold
50
– – ﹤0.01% 381
2020
Q4 		$8K Hold
50
– – ﹤0.01% 362
2020
Q3 		$4K Buy
+50
New +$3.49K ﹤0.01% 433

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Asset Management's MRNA Position: Q2 2022 in Review

Bellevue Asset Management sold out of Moderna (MRNA) in Q2 2022, closing a stake of 50 shares — an estimated $9K sold.

Bellevue Asset Management first reported a position in MRNA in Q3 2020 and held it in 7 quarters. The position peaked at $19K in Q3 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Bellevue Asset Management reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • Bellevue Asset Management sold 50 Moderna shares in Q2 2022, an estimated $9K.
  • Bellevue Asset Management first reported a position in Moderna in Q3 2020 and held it in 7 quarters.
  • Bellevue Asset Management's Moderna position peaked at $19K in Q3 2021.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Bellevue Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.